Squarepoint
GLUE icon

Squarepoint’s Monte Rosa Therapeutics GLUE Stock Holding History

Squarepoint’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$610K Buy
37,107
+27,078
+270% +$518K ﹤0.01% 3176
2025
Q4 		$157K Sell
10,029
-84,678
-89% -$1.14M ﹤0.01% 3938
2025
Q3 		$702K Sell
94,707
-83,429
-47% -$442K ﹤0.01% 2948
2025
Q2 		$803K Buy
+178,136
New +$795K ﹤0.01% 2859
2025
Q1 		– Sell
-31,654
Closed -$220K – 4891
2024
Q4 		$220K Buy
+31,654
New +$238K ﹤0.01% 4397
2024
Q3 		– Sell
-22,665
Closed -$84.8K – 4316
2024
Q2 		$84.8K Buy
+22,665
New +$116K ﹤0.01% 3825
2024
Q1 		– Sell
-17,462
Closed -$98.7K – 4224
2023
Q4 		$98.7K Buy
+17,462
New +$68.5K ﹤0.01% 3756
2023
Q2 		– Sell
-13,998
Closed -$109K – 3720
2023
Q1 		$109K Buy
+13,998
New +$97.3K ﹤0.01% 2956
2022
Q4 		– Sell
-28,410
Closed -$232K – 3331
2022
Q3 		$232K Buy
28,410
+13,108
+86% +$120K ﹤0.01% 2622
2022
Q2 		$148K Buy
+15,302
New +$154K ﹤0.01% 2552
2021
Q3 		– Sell
-28,209
Closed -$640K – 3096
2021
Q2 		$640K Buy
+28,209
New +$575K ﹤0.01% 1962

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Squarepoint's GLUE Position: Q1 2026 in Review

Squarepoint increased its Monte Rosa Therapeutics (GLUE) stake by 270% in Q1 2026, buying an estimated $518K and bringing the position to 37,107 shares worth $610K. The position accounts for ﹤0.01% of the portfolio, ranked #3176.

Squarepoint first reported a position in GLUE in Q2 2021 and has held it in 11 quarters since. The position peaked at $803K in Q2 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Squarepoint held 37,107 shares of Monte Rosa Therapeutics worth $610K as of Q1 2026.
  • Squarepoint bought 27,078 Monte Rosa Therapeutics shares in Q1 2026, an estimated $518K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3176 holding.
  • Squarepoint first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • Squarepoint's Monte Rosa Therapeutics position peaked at $803K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.